Status:
UNKNOWN
Topical Diclofenac on Macular Thickness After Phacoemulsification
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Diabetic Oculopathy
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Eyes of 108 diabetic patients have underwent phacoemulsification and intraocular lens implantation surgery have enrolled. Fifty four eyes have received the conventional postoperative care with steroid...
Eligibility Criteria
Inclusion
- Diabetic patients with non-proliferative diabetic retinopathy that were candidate for phacoemulsification and intraocular lens implantation
Exclusion
- Eyes with clinically significant macular edema based on the ETDRS(Early Treatment Diabetic Retinopathy Study) study and/or central macular thickness \>260µ were not included. Neither did we include the eyes with other accompanying diseases affecting the macula or eyes with history of previous retinal laser photocoagulation or intraocular surgery.
- Eyes with severe cataract that preclude performing an acceptable quality optical coherence tomography (OCT) were not enrolled either.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT02306031
Start Date
June 1 2013
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Labbafinejad medical center
Tehran, Iran